Burosumab for treating X-linked hypophosphataemia in children and young people

  • Highly specialised technologies guidance
  • HST8
  • Published: 
  • Last updated: 
Download guidance (PDF)

Update information

September 2024: Recommendation 1.1 has been amended to match the updated marketing authorisation for burosumab, which has also been updated in section 3.1.

ISBN: 978-1-4731-6502-1